Fortress Biotech Inc Pref Series A (FBIOP)vsNovartis AG ADR (NVS)
FBIOP
Fortress Biotech Inc Pref Series A
$20.43
-0.24%
HEALTHCARE · Cap: $77.81M
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 89334% more annual revenue ($56.58B vs $63.26M). NVS leads profitability with a 23.9% profit margin vs 10.8%. NVS earns a higher WallStSmart Score of 49/100 (D+).
FBIOP
Avoid28
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.2%
Fair Value
$13.03
Current Price
$20.43
$7.40 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 79 in profit
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 12.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : FBIOP
The primary concerns for FBIOP are Price/Book, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
FBIOP profiles as a value stock while NVS is a declining play — different risk/reward profiles.
FBIOP carries more volatility with a beta of 1.16 — expect wider price swings.
FBIOP is growing revenue faster at 6.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 28/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?